ScripChinese biotechs are racing to push back the frontiers of combination therapies for antibody-drug conjugates (ADCs), progressing multiple assets into mid-stage clinical development. Beyond the validat
ScripA new wave of mid-sized biopharma companies is being created in China, driven on by in-house R&D and big pharma licensing deals. That is the picture emerging from data captured by Evaluate Pharma
ScripThere were fireworks ahead of the 4th of July festivities over the pharma sector as analysts weighed in on the rumors that a multi-billion dollar deal is in the offing between AstraZeneca and Summit T
In VivoIn the top alliance by deal value, Pfizer entered into an exclusive global, ex-China, licensing agreement with 3SBio for the development, manufacturing, and commercialization of SSGJ-707, a bispecific